4967 Kobayashi Pharmaceutical
- 6337.0
- +164.0+2.66%
Kobayashi Pharmaceutical News
Express News | The Osaka government in Japan instructed Kobayashi Pharmaceutical to dispose of approximately 416,000 products.
Kobayashi Pharmaceutical: Extraordinary Report
Kobayashi Pharmaceutical To Go Ex-Dividend On December 27th, 2024 With 59 JPY Dividend Per Share
December 26th (Japan Standard Time) - $Kobayashi Pharmaceutical(4967.JP)$ is trading ex-dividend on December 27th, 2024.Shareholders of record on December 31st, 2024 will receive 59 JPY dividend per
Express News | Oasis Management Raises Stake in Kobayashi Pharmaceutical to 10.1% From 7.54%, Filing Shows
Goldman Sachs: The yen has dropped to a value point, creating the best opportunity for foreign capital to Buy Japanese stocks.
Goldman Sachs believes that the yen is the best choice for global Japanese stock buyers.
Intertrade Research Memo (5): The fiscal year ending September 2024 will see a decrease in revenue and a significant drop in profit. The main financial solutions will be a burden.
■ The performance trend of Intertrade <3747> 1. Performance for the fiscal year ending September 2024 The consolidated performance for the fiscal year ending September 2024 shows revenue of 1,849 million yen (a decrease of 8.1% from the previous year), operating profit of 80 million yen (a decrease of 59.8% from the previous year), ordinary loss of 159 million yen (compared to a profit of 1 million yen in the previous year), and a net loss attributable to the parent company's Shareholders of 97 million yen (compared to a profit of 36 million yen in the previous year), resulting in a landing below the initial plan in all items. In terms of revenue, the Business Solutions segment has increased revenue by 16.1%.
Japan M&A Center, DIC, ETC (additional) Rating
Target Price Change Code Stock Name Securities Company Previous Change After ----------------------------------------------- <2127> Japan M&A Center Nomura 950 yen 760 yen <4631> DIC Nomura 4000 yen 4300 yen <4634> artience Nomura 4900 yen 4200 yen <7181> Japan Post Insurance Nomura 3600 yen 3700 yen <3405> Kuraray Okasan 2400 yen 3000 yen <4919> Milbon Daiwa 36
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
○ List of stocks that have switched to Sell market Code Stock Name Closing Price SAR Main Board <1414> Showa Bond 5198 5346 <1726> Br. HD 335338 <1808> Nagase & Co. 20122066 <1941> Chudenko 33153530 <1945> Tokyo Enesis 10381072 <1959> Kyudenko 50875319 <2198> Aikik 730748 <2207> Meito Sangyo
Set a historical record! Aggressive investors are flocking to Japan Stocks, with over 1 trillion yen bought this year to date.
The obsession of radical investors with Japan Assets has reached record levels. Their influence is likewise significant.
The Japanese economy is experiencing a "dual situation of ice and fire"! Manufacturing continues to shrink, while the service industry rises against the trend.
Japan's economy continued to see a contraction in manufacturing activity in December, entering its sixth month of contraction, while the services sector maintained a growth trend.
Announcement of the record date for the convening of the extraordinary Shareholders' Meeting.
Announcement regarding the setting of the record date for the extraordinary Shareholder meeting to be held on December 13, 2024. The board of directors held today decided the record date for voting rights in the extraordinary Shareholder meeting (hereinafter referred to as "this extraordinary Shareholder meeting") planned to be held within three months from December 31, 2024 (Tuesday), as follows: 1. Regarding the record date, etc., for this extraordinary Shareholder meeting, we will decide the voting rights.
Reports indicate that the Bank of Japan will "hold steady" next week, and Bank of America expects the interest rate hike may be postponed until March next year.
Five sources familiar with the thoughts of the Bank of Japan stated that the Bank is inclined to keep interest rates unchanged next week. However, Bank of America warned that if the Bank of Japan continues to delay interest rate hikes until March next year, the yen could depreciate again to 155 or slightly below the 157 level reached in November.
The Bank of Japan's interest rate decision will be announced next week. Will global stock markets repeat 'Black Monday'?
The Bank of Japan will hold its last monetary policy meeting of the year next week.
Yen surges! Has the Bank of Japan decided not to raise interest rates?
Officials from the Bank of Japan believe that there is almost no cost in waiting for the next rate hike, and the yen plummeted upon hearing this.....
Is an interest rate hike being hinted at? The Bank of Japan has unusually scheduled a speech and press conference for January.
Analysis suggests that regional speeches generally provide council members with more freedom to express their views on mmf policy, and also give central banks the opportunity to allow market participants to adjust their expectations. An increasing number of economists expect that the central bank will raise interest rates at the January meeting.
Japan's basic salary increase in October reached a record high, creating conditions for the central bank to raise interest rates again.
Japan's official employees' basic wage increase hit a record high, further indicating that the Japanese economy is moving towards a positive cyclical development, which will support market speculation on the recent interest rate hike by the Bank of Japan.
Kobayashi Pharmaceutical's Hong Kong shareholders file lawsuit against 7 former senior executives over red yeast rice product incident, claiming over 10 billion yen.
According to the Nikkei Chinese website, Oasis Management, a Hong Kong investment fund holding over 7% stake in Kobayashi Pharmaceutical, recently demanded Kobayashi Pharmaceutical to sue the former chairman and 7 other individuals, claiming over 10 billion yen, and warned that if Kobayashi Pharmaceutical directors do not take action on behalf of the company, Oasis may file a shareholder representative lawsuit at the end of January next year. According to reports, Kobayashi Pharmaceutical incurred special losses of over 10 billion yen during the period from January to September this year due to expenses related to the red mold issue; based on a large number of shareholding reports, Oasis has been shareholding Kobayashi Pharmaceutical stocks.
The Hong Kong investment fund has filed a lawsuit in the japan court against senior executives of Kobayashi Pharmaceutical, claiming over 0.5 billion yuan.
According to the "Japan Economic News," Oasis Management, an investment fund from Hong Kong, filed a lawsuit late last month regarding the health hazard issues caused by the health products containing red yeast rice ingredients from Kobayashi Pharmaceutical, demanding compensation of over 10 billion yen (0.52 billion HKD) from seven individuals, including both former and current senior executives of the company. The defendants include all directors at the time the issue was exposed, including former Chairman Kazumasa Kobayashi, former President Akihiro Kobayashi, current President Satoshi Yamane, honorary professor Kunio Ito from Hitotsubashi University, and external directors such as Kaori Sasaki, president of Ewoman. Kobayashi Pharmaceutical has faced issues related to red yeast rice in the first three quarters of this year.
Express News | Suit Would Seek Over 10 Bln Yen to Redress Damages Caused by Scandal Concerning Red Yeast Supplement Linked to Scores of Deaths - Nikkei
Express News | Market news: OASIS Company has filed a lawsuit against Kobayashi Pharmaceutical Company, seeking compensation of 67 million dollars from its executives.
No Data